Jump to content Main menu Main menu move to sidebar hide Navigation Main page Contents Current events Random article About Wikipedia Contact us Contribute Help Learn to edit Community portal Recent changes Upload file Special pages Search Search Appearance Donate Create account Log in Personal tools Donate Create account Log in Pages for logged out editors learn more Contributions Talk CentralNotice Contents move to sidebar hide (Top) 1 Medical uses Toggle Medical uses subsection 1.1 Cancer 1.2 Other uses 2 Side effects Toggle Side effects subsection 2.1 Lifetime cumulative dose 3 Mechanism of action 4 Biosynthesis 5 History 6 Research 7 See also 8 References 9 Further reading Toggle the table of contents Bleomycin 27 languages العربية تۆرکجه Català Cymraeg Deutsch Español فارسی Français 한국어 Հայերեն Bahasa Indonesia Italiano עברית Nederlands 日本語 ଓଡ଼ିଆ Polski Português Română Русский Српски / srpski Srpskohrvatski / српскохрватски Suomi Türkçe Українська Tiếng Việt 中文 Edit links Article Talk English Read Edit View history Tools Tools move to sidebar hide Actions Read Edit View history General What links here Related changes Upload file Permanent link Page information Cite this page Get shortened URL Download QR code Print/export Download as PDF Printable version In other projects Wikimedia Commons Wikidata item Appearance move to sidebar hide From Wikipedia, the free encyclopedia Glycopeptide antibiotic used to treat various cancers Pharmaceutical compound Bleomycin Bleomycin A2 Clinical data Trade names Blenoxane AHFS / Drugs.com Monograph MedlinePlus a682125 License data US DailyMed : Bleomycin Pregnancy category AU : D [ 1 ] Routes of administration intravenous , intramuscular , subcutaneous , intrapleural [ 2 ] Drug class Glycopeptide antibiotic ATC code L01DC01 ( WHO ) Legal status Legal status UK : POM (Prescription only) [ 3 ] US : ℞-only EU : Rx-only [ 4 ] Pharmacokinetic data Bioavailability 100% and 70% following intramuscular and subcutaneous administrations, respectively, and 45% following both intraperitoneal and intrapleural administrations [ 2 ] Elimination half-life two hours [ 2 ] Excretion Kidney (60–70%) [ 2 ] Identifiers IUPAC name (3-{[(2'-{(5 S ,8 S ,9 S ,10 R ,13 S )-15-{6-amino-2- [(1 S )-3-amino-1-{[(2 S )-2,3-diamino-3-oxopropyl]amino}-3-oxopropyl] -5-methylpyrimidin-4-yl}-13-[{[(2 R ,3 S ,4 S ,5 S ,6 S )-3- {[(2 R ,3 S ,4 S ,5 R ,6 R )-4-(carbamoyloxy)-3,5-dihydroxy-6- (hydroxymethyl)tetrahydro-2 H -pyran-2-yl]oxy} -4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2 H -pyran-2-yl]oxy} (1 H -imidazol-5-yl)methyl]-9-hydroxy-5-[(1 R )-1-hydroxyethyl]-8,10-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazapentadec-1-yl}-2,4'-bi-1,3-thiazol-4-yl)carbonyl]amino}propyl)(dimethyl)sulfonium CAS Number 11056-06-7 Y sulfate: 9041-93-4 Y PubChem CID 5460769 DrugBank DB00290 N ChemSpider 4574226 N UNII 40S1VHN69B sulfate: 7DP3NTV15T Y KEGG D07535 N sulfate: C15773 N ChEBI CHEBI:22907 N ChEMBL ChEMBL403664 N CompTox Dashboard ( EPA ) DTXSID1030862 Chemical and physical data Formula C 55 H 84 N 17 O 21 S 3 Molar mass 1 415 .56 g·mol −1 3D model ( JSmol ) Interactive image SMILES CC1=C(N=C(N=C1N)[C@H](CC(=O)N)NC[C@@H](C(=O)N)N)C(=O)N[C@@H](C(C2=CN=CN2)O[C@H]3[C@H]([C@H]([C@@H]([C@@H](O3)CO)O)O)O[C@@H]4[C@H]([C@H]([C@@H]([C@H](O4)CO)O)OC(=O)N)O)C(=O)N[C@H](C)[C@H]([C@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O InChI InChI=1S/C55H83N17O21S3/c1-20-33(69-46(72-44(20)58)25(12-31(57)76)64-13-24(56)45(59)82)50(86)71-35(41(26-14-61-19-65-26)91-54-43(39(80)37(78)29(15-73)90-54)92-53-40(81)42(93-55(60)88)38(79)30(16-74)89-53)51(87)66-22(3)36(77)21(2)47(83)70-34(23(4)75)49(85)63-10-8-32-67-28(18-94-32)52-68-27(17-95-52)48(84)62-9-7-11-96(5)6/h14,17-19,21-25,29-30,34-43,53-54,64,73-75,77-81H,7-13,15-16,56H2,1-6H3,(H13-,57,58,59,60,61,62,63,65,66,69,70,71,72,76,82,83,84,85,86,87,88)/p+1/t21-,22+,23+,24-,25-,29-,30+,34-,35-,36-,37+,38+,39-,40-,41-,42-,43-,53+,54-/m0/s1 N Key:OYVAGSVQBOHSSS-UAPAGMARSA-O N N Y (what is this?) (verify) Bleomycin is a medication primarily used to treat cancer .

[ 5 ] This includes Hodgkin's lymphoma , non-Hodgkin's lymphoma , testicular cancer , ovarian cancer , and cervical cancer among others.

[ 5 ] Typically used with other cancer medications , [ 5 ] it can be given intravenously, by injection into a muscle or under the skin.

[ 5 ] It may also be administered inside the chest to help prevent the recurrence of a pleural effusion due to cancer; however talc is better for this.

[ 5 ] [ 6 ] It may sometimes be used to treat other difficult-to-treat skin lesions such as plantar warts in immunocompromised patients.

Common side effects include fever , weight loss, vomiting, and rash.

[ 5 ] A severe type of anaphylaxis may occur.

[ 5 ] It may also cause inflammation of the lungs that can result in lung scarring .

[ 5 ] Chest X-rays every couple of weeks are recommended to check for this.

[ 5 ] Bleomycin may cause harm to the baby if used during pregnancy.

[ 5 ] It is believed to primarily work by preventing the synthesis of DNA .

[ 5 ] Bleomycin was discovered in 1962.

[ 7 ] [ 8 ] It is on the World Health Organization's List of Essential Medicines .

[ 9 ] It is available as a generic medication .

[ 5 ] It is made by the bacterium Streptomyces verticillus .

[ 5 ] Medical uses [ edit ] Cancer [ edit ] Bleomycin is mostly used to treat cancer .

[ 5 ] This includes testicular cancer , ovarian cancer , and Hodgkin's disease , and less commonly non-Hodgkin's disease .

[ 5 ] It can be given intravenously, by intramuscular injection, or under the skin.

[ 5 ] Other uses [ edit ] It may also be put inside the chest to help prevent the recurrence of a pleural effusion due to cancer.

[ 5 ] However, for scarring down the pleura , talc appears to be the better option although indwelling pleural catheters are at least as effective in reducing the symptoms of an effusion(such as dyspnea).

[ 10 ] [ 11 ] While potentially effective against bacterial infections, its toxicity prevents its use for this purpose.

[ 5 ] It has been studied in the treatment of warts but is of unclear benefit.

[ 12 ] Side effects [ edit ] The most common side effects are flu-like symptoms and include fever , rash, dermatographism , hyperpigmentation , alopecia (hair loss), chills, and Raynaud's phenomenon (discoloration of fingers and toes). The most serious complication of bleomycin, occurring upon increasing dosage, is pulmonary fibrosis and impaired lung function. It has been suggested that bleomycin induces sensitivity to oxygen toxicity [ 13 ] and recent studies support the role of the proinflammatory cytokines IL-18 and IL-1beta in the mechanism of bleomycin-induced lung injury.

[ 14 ] Any previous treatment with bleomycin should therefore always be disclosed to the anaesthetist prior to undergoing a procedure requiring general anaesthesia . Due to the oxygen sensitive nature of bleomycin, and the theorised increased likelihood of developing pulmonary fibrosis following supplemental oxygen therapy, it has been questioned whether patients should take part in scuba diving following treatment with the drug.

[ 15 ] Bleomycin has also been found to disrupt the sense of taste .

[ 16 ] Lifetime cumulative dose [ edit ] Bleomycin should not exceed a lifetime cumulative dose greater than 400 units.

[ 17 ] Pulmonary toxicities, most commonly presenting as pulmonary fibrosis , are associated with doses of bleomycin greater than 400 units.

[ 17 ] Mechanism of action [ edit ] Bleomycin acts by induction of DNA strand breaks.

[ 18 ] Some studies suggest bleomycin also inhibits incorporation of thymidine into DNA strands. DNA cleavage by bleomycin depends on oxygen and metal ions, at least in vitro . The exact mechanism of DNA strand scission is unresolved, but it has been suggested that bleomycin chelates metal ions (primarily iron), producing a pseudoenzyme that reacts with oxygen to produce superoxide and hydroxide free radicals that cleave DNA. An alternative hypothesis states that bleomycin may bind at specific sites in the DNA strand and induce scission by abstracting the hydrogen atom from the base, resulting in strand cleavage as the base undergoes a Criegee-type rearrangement , or forms an alkali-labile lesion.

[ 19 ] Biosynthesis [ edit ] Biosynthesis of bleomycin is completed by glycosylation of the aglycones.  Bleomycin naturally occurring-analogues have two to three sugar molecules, and DNA cleavage activities of these analogues have been assessed, [ 20 ] [ 21 ] primarily by the plasmid relaxation and break light assays.

History [ edit ] See also: History of cancer chemotherapy Bleomycin was first discovered in 1962 when the Japanese scientist Hamao Umezawa found anticancer activity while screening culture filtrates of Streptomyces verticillus . Umezawa published his discovery in 1966.

[ 22 ] The drug was launched in Japan by Nippon Kayaku in 1969. In the US, bleomycin gained FDA approval in July 1973. It was initially marketed in the US by the Bristol-Myers Squibb precursor, Bristol Laboratories, under the brand name Blenoxane.

Research [ edit ] Bleomycin is used in research to induce pulmonary fibrosis in mice.

[ 23 ] It accomplishes this by preventing alveolar cell proliferation, which in turn leads to cellular senescence .

See also [ edit ] Flagellate pigmentation from bleomycin Pingyangmycin (Bleomycin A 5 ) References [ edit ] ^ "Bleomycin Use During Pregnancy" .

Drugs.com . 9 August 2019 . Retrieved 16 February 2020 .

^ a b c d "Bleomycin- bleomycin sulfate injection, powder, lyophilized, for solution" .

DailyMed . 31 December 2019 . Retrieved 16 February 2020 .

^ "Bleo-Kyowa Powder for solution for injection - Summary of Product Characteristics (SmPC)" .

(emc) . 31 August 2018. Archived from the original on 16 February 2020 . Retrieved 16 February 2020 .

^ "Bleomycin" .

European Medicines Agency (EMA) . 18 March 2009.

^ a b c d e f g h i j k l m n o p q r "Bleomycin Sulfate" . The American Society of Health-System Pharmacists.

Archived from the original on 8 September 2015 . Retrieved 1 August 2015 .

^ Dipper A, Jones HE, Bhatnagar R, Preston NJ, Maskell N, Clive AO (April 2020).

"Interventions for the management of malignant pleural effusions: a network meta-analysis" .

The Cochrane Database of Systematic Reviews .

2020 (4): CD010529.

doi : 10.1002/14651858.CD010529.pub3 .

PMC 7173736 .

PMID 32315458 .

^ Sneader W (2005).

Drug discovery : a history (Rev. and updated ed.). Chichester: Wiley. p. 312.

ISBN 9780471899792 .

Archived from the original on 5 March 2016.

^ Phillips GO (2018).

Innovation and Technology Transfer in Japan and Europe: Industry-Academic Interactions . Routledge. p. PT155.

ISBN 9780429774546 .

^ World Health Organization (2019).

World Health Organization model list of essential medicines: 21st list 2019 . Geneva: World Health Organization.

hdl : 10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

^ Shaw P, Agarwal R (2004). Shaw PH (ed.). "Pleurodesis for malignant pleural effusions".

The Cochrane Database of Systematic Reviews (1): CD002916.

doi : 10.1002/14651858.CD002916.pub2 .

PMID 14973997 .

(Retracted, see doi : 10.1002/14651858.CD002916.pub3 , PMID 24259053 ) ^ Thomas R, Murray K, Lee YC (April 2018). "Treatment Approaches for Malignant Pleural Effusion".

JAMA .

319 (14): 1507– 1508.

doi : 10.1001/jama.2018.1323 .

PMID 29634827 .

^ Kwok CS, Gibbs S, Bennett C, Holland R, Abbott R (September 2012).

"Topical treatments for cutaneous warts" .

The Cochrane Database of Systematic Reviews .

9 (9): CD001781.

doi : 10.1002/14651858.CD001781.pub3 .

PMC 8101088 .

PMID 22972052 .

^ Thompson M.

"Bleomycin and Anaesthesia" (PDF) .

Anaesthesia Western Australia . Archived from the original (PDF) on 8 September 2017 . Retrieved 8 September 2017 .

^ Hoshino T, Okamoto M, Sakazaki Y, Kato S, Young HA, Aizawa H (December 2009).

"Role of proinflammatory cytokines IL-18 and IL-1beta in bleomycin-induced lung injury in humans and mice" .

American Journal of Respiratory Cell and Molecular Biology .

41 (6): 661– 670.

doi : 10.1165/rcmb.2008-0182OC .

PMC 10283344 .

PMID 19265174 .

^ Huls G, ten Bokkel Huinink D (February 2003). "Bleomycin and scuba diving: to dive or not to dive?".

The Netherlands Journal of Medicine .

61 (2): 50– 53.

PMID 12735422 .

^ Ackerman BH, Kasbekar N (1997). "Disturbances of taste and smell induced by drugs".

Pharmacotherapy .

17 (3): 482– 496.

doi : 10.1002/j.1875-9114.1997.tb03058.x .

PMID 9165552 .

S2CID 12671326 .

^ a b "bleomycin [TUSOM | Pharmwiki]" .

tmedweb.tulane.edu . Retrieved 2 February 2022 .

^ Takimoto CH, Calvo E (2008).

"Principles of Oncologic Pharmacotherapy" . In Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ (eds.).

Cancer Management: A Multidisciplinary Approach . Vol. 3 (11th ed.). UBM Medica LLC. Archived from the original on 15 May 2009.

^ Hecht SM (January 2000). "Bleomycin: new perspectives on the mechanism of action".

Journal of Natural Products .

63 (1): 158– 168.

Bibcode : 2000JNAtP..63..158H .

doi : 10.1021/np990549f .

PMID 10650103 .

^ Hindra, Yang D, Teng Q, Dong LB, Crnovčić I, Huang T, et al. (March 2017). "Genome Mining of Streptomyces mobaraensis DSM40847 as a Bleomycin Producer Providing a Biotechnology Platform To Engineer Designer Bleomycin Analogues".

Organic Letters .

19 (6): 1386– 1389.

doi : 10.1021/acs.orglett.7b00283 .

PMID 28256838 .

^ Yang D, Hindra, Dong LB, Crnovcic I, Shen B (August 2017).

"Engineered production and evaluation of 6'-deoxy-tallysomycin H-1 revealing new insights into the structure-activity relationship of the anticancer drug bleomycin" .

The Journal of Antibiotics .

71 : 97– 103.

doi : 10.1038/ja.2017.93 .

PMID 28831149 .

S2CID 33531845 .

^ Umezawa H, Maeda K, Takeuchi T, Okami Y (September 1966). "New antibiotics, bleomycin A and B".

The Journal of Antibiotics .

19 (5): 200– 9.

PMID 5953301 .

^ Song N, Liu J, Shaheen S, Du L, Proctor M, Roman J, et al. (August 2015).

"Vagotomy attenuates bleomycin-induced pulmonary fibrosis in mice" .

Scientific Reports .

5 13419.

Bibcode : 2015NatSR...513419S .

doi : 10.1038/srep13419 .

PMC 4542162 .

PMID 26289670 .

In our studies, mice developed classic PF with structural alteration of the lung following intravenous bleomycin treatment Further reading [ edit ] Claussen CA, Long EC (September 1999). "Nucleic Acid recognition by metal complexes of bleomycin".

Chemical Reviews .

99 (9): 2797– 2816.

doi : 10.1021/cr980449z .

PMID 11749501 .

Shen B, Du L, Sanchez C, Edwards DJ, Chen M, Murrell JM (December 2001).

"The biosynthetic gene cluster for the anticancer drug bleomycin from Streptomyces verticillus ATCC15003 as a model for hybrid peptide-polyketide natural product biosynthesis" .

Journal of Industrial Microbiology & Biotechnology .

27 (6): 378– 385.

doi : 10.1038/sj.jim.7000194 .

PMID 11774003 .

S2CID 3022217 .

v t e Intracellular chemotherapeutic agents / antineoplastic agents ( L01 ) SPs / MIs ( M phase ) Block microtubule assembly Vinca alkaloids ( Vinblastine # Vincristine # Vindesine Vinflunine § Vinorelbine # ) Block microtubule disassembly Taxanes ( Cabazitaxel Docetaxel # Larotaxel Ortataxel † Paclitaxel # Tesetaxel ) Epothilones ( Ixabepilone ) DNA replication inhibitor DNA precursors/ antimetabolites ( S phase ) Folic acid Dihydrofolate reductase inhibitor ( Aminopterin Methotrexate # Pemetrexed Pralatrexate ) Thymidylate synthase inhibitor ( Pemetrexed Raltitrexed ) Purine Adenosine deaminase inhibitor ( Pentostatin ) Halogenated / ribonucleotide reductase inhibitors ( Cladribine Clofarabine Fludarabine ) Nelarabine Rabacfosadine Thiopurine ( Mercaptopurine # Tioguanine # ) Pyrimidine Thymidylate synthase inhibitor ( Capecitabine # Carmofur Doxifluridine Floxuridine Fluorouracil # Tegafur ( +gimeracil/oteracil )) DNA polymerase inhibitor ( Cytarabine # +daunorubicin ) Ribonucleotide reductase inhibitor ( Gemcitabine # ) Hypomethylating agent ( Azacitidine Decitabine ) Deoxyribonucleotide Ribonucleotide reductase inhibitor ( Hydroxycarbamide # ) Topoisomerase inhibitors ( S phase ) I Camptotheca ( Belotecan Camptothecin Cositecan † Etirinotecan pegol † Exatecan Gimatecan Irinotecan # Lurtotecan ‡ Rubitecan ‡ Silatecan § Topotecan ) II Podophyllum ( Etoposide # Teniposide ) II + Intercalation Anthracyclines ( Aclarubicin Amrubicin † Daunorubicin # ( +cytarabine ) Doxorubicin # Epirubicin Idarubicin Pirarubicin Valrubicin Zorubicin ) Anthracenediones ( Losoxantrone Mitoxantrone Pixantrone ) Amsacrine Bisantrene Crisnatol Menogaril § Crosslinking of DNA ( CCNS ) Alkylating Nitrogen mustards : Bendamustine # Chlormethine Cyclophosphamide # ( Ifosfamide # Trofosfamide ) Chlorambucil # Melphalan ( Melphalan flufenamide ) Prednimustine Uramustine Nitrosoureas : Carmustine Fotemustine Lomustine ( Semustine ) Nimustine Ranimustine Streptozocin Alkyl sulfonates : Busulfan ( Mannosulfan Treosulfan ) Aziridines : Carboquone Thiotepa Triaziquone Triethylenemelamine Platinum-based Carboplatin # Cisplatin # Dicycloplatin Nedaplatin Oxaliplatin # Satraplatin Nonclassical Altretamine Hydrazines ( Procarbazine # ) Etoglucid Mitobronitol Pipobroman Triazenes ( Dacarbazine # Mitozolomide § Temozolomide ) Intercalation Streptomyces ( Dactinomycin # Bleomycin # Ixabepilone Mitomycin Plicamycin Utidelone ) Photosensitizers / PDT Aminolevulinic acid Efaproxiral Methyl aminolevulinate Padeliporfin Porphyrin derivatives ( Porfimer sodium Talaporfin Temoporfin Verteporfin ) Other Enzyme inhibitors FI ( Tipifarnib § ) CDK inhibitors ( Abemaciclib Alvocidib † Palbociclib Ribociclib Seliciclib † ) PrI Bortezomib Carfilzomib Oprozomib Ixazomib PhI ( Anagrelide ) IMPDI ( Tiazofurin § ) LI ( Masoprocol ) PARP inhibitor ( Fuzuloparib Niraparib +abiraterone acetate Olaparib Rucaparib ) HDAC ( Belinostat Entinostat Panobinostat Romidepsin Vorinostat ) PIKI (Pi3K) ( Alpelisib Copanlisib ‡ Duvelisib Idelalisib Inavolisib Umbralisib ‡ ) IDH ( Enasidenib Ivosidenib Olutasidenib Vorasidenib ) Receptor antagonists ERA ( Atrasentan ) Retinoid X receptor ( Bexarotene ) Sex steroid ( Testolactone ) Other/ungrouped Adagrasib Aflibercept Arsenic trioxide Asparagine depleters ( Asparaginase # / Pegaspargase ) Axicabtagene ciloleucel Belzutifan Bexarotene Brexucabtagene autoleucel Calaspargase pegol Celecoxib Ciltacabtagene autoleucel Darinaparsin Demecolcine Denileukin diftitox Eflornithine Elesclomol § Elsamitrucin Epacadostat Eribulin Estramustine Glasdegib Idecabtagene vicleucel Idroxioleic acid Imetelstat Lifileucel Lisocabtagene maraleucel Lonidamine Lucanthone Lurbinectedin Mitoguazone Mitotane Nadofaragene firadenovec Navitoclax Nirogacestat Obecabtagene autoleucel Oblimersen † Omacetaxine mepesuccinate Para-toluenesulfonamide Pelabresib Plitidepsin Retinoids ( Alitretinoin Tretinoin # ) Selinexor Sitimagene ceradenovec Sotorasib Tabelecleucel Tagraxofusp Talimogene laherparepvec Tazemetostat Tebentafusp Tiazofurine Tigilanol tiglate Tisagenlecleucel Trabectedin Veliparib Venetoclax Verdinexor Vosaroxin # WHO-EM ‡ Withdrawn from market Clinical trials : † Phase III § Never to phase III Portal : Medicine Retrieved from " https://en.wikipedia.org/w/index.php?title=Bleomycin&oldid=1306510478 " Categories : Cancer research DNA intercalaters DNA replication inhibitors Glycopeptide antibiotics IARC Group 2B carcinogens Sulfonium compounds World Health Organization essential medicines Eukaryotic selection compounds Hydroxymethyl compounds Japanese inventions Hidden categories: CS1:Vancouver names with accept markup Articles intentionally citing retracted publications Articles with short description Short description is different from Wikidata Use dmy dates from May 2022 Drugs with non-standard legal status Articles with changed DrugBank identifier Articles with changed ChemSpider identifier Articles with changed KEGG identifier Articles with changed EBI identifier Articles with changed InChI identifier Multiple chemicals in Infobox drug Chemicals using indexlabels Chemical articles with multiple CAS registry numbers Drugboxes which contain changes to verified fields Drugboxes which contain changes to watched fields Wikipedia medicine articles ready to translate This page was last edited on 18 August 2025, at 03:39 (UTC) .

Text is available under the Creative Commons Attribution-ShareAlike 4.0 License ;
additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy . Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.

, a non-profit organization.

Privacy policy About Wikipedia Disclaimers Contact Wikipedia Code of Conduct Developers Statistics Cookie statement Mobile view Search Search Toggle the table of contents Bleomycin 27 languages Add topic

